Form 4: CorMedix Officer's Stock Transactions & RSU Grant

CorMedix Chief Legal Officer Beth Zelnick Kaufman reported the grant of 72,820 restricted stock units and the disposition of 8,803 shares for tax withholding.

Summary

• Beth Zelnick Kaufman, CorMedix Inc.'s Chief Legal Officer, reported transactions in company common stock.
• On January 23, 2026, she was granted 72,820 restricted stock units (RSUs).
• Each RSU represents the right to receive one share of CorMedix Inc. common stock.
• These RSUs vest 1/4 on the date of grant, and 1/4 on the first, second, and third anniversaries of the grant date, subject to continued employment.
• Following the RSU grant, her direct beneficial ownership initially increased to 241,905 shares.
• Also on January 23, 2026, she disposed of 8,803 shares of common stock at a price of $7.27 per share, likely for tax withholding purposes.
• After this disposition, her direct beneficial ownership stands at 233,102 shares.
• A Power of Attorney was executed on January 14, 2026, appointing Susan Blum as attorney-in-fact for Beth Zelnick Kaufman to handle SEC filings (Forms ID, 3, 4, 5, 144).

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is generally a positive sign of alignment and retention, despite the minor disposition for tax purposes, which is a routine event.

Positives

• The grant of 72,820 restricted stock units to a key executive aligns management's interests with long-term shareholder value.
• The multi-year vesting schedule for the RSUs encourages executive retention and sustained performance.

Negatives

• The disposition of 8,803 shares at $7.27 per share, while likely for tax purposes, represents a reduction in direct shareholdings.

Risks

• The Power of Attorney explicitly states that the attorney-in-fact and the Company are not assuming Beth Zelnick Kaufman's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended, highlighting individual compliance responsibility.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's operational performance, financial health, or strategic direction.

Industry Context

This filing is a routine insider transaction report, detailing an executive's equity compensation and related stock movements. It does not provide information for broader industry trend analysis or competitive positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns executive interests with long-term shareholder value, while the disposition for tax purposes is a routine event with minimal impact.
• Employees: The vesting schedule for RSUs serves as a common incentive mechanism for executive retention and performance.

Next Steps

• Vesting of the remaining 3/4 of the restricted stock units on the first, second, and third anniversaries of January 23, 2026, subject to continued employment.

Key Dates

Recommendation

The filing details a routine executive equity grant and a corresponding tax-related disposition. While the RSU grant aligns executive incentives with long-term shareholder value, it does not present new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

CorMedix Inc., CRMD, SEC Form 4, Restricted Stock Units, RSU Grant, Insider Trading, Beneficial Ownership, Executive Compensation, Power of Attorney